Gynecologic Oncology Reports最新文献

{"title":"Attitudes towards opportunistic salpingectomy among patients planned to undergo non-gynecologic intra-abdominal surgery","authors":"Monali S. Ardeshna ,&nbsp;Lauren Dori ,&nbsp;Benjamin Margolis","doi":"10.1016/j.gore.2025.102000","DOIUrl":"10.1016/j.gore.2025.102000","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the knowledge of and interest in opportunistic salpingectomy (OS) in patients undergoing non-gynecologic abdominal surgery.</div></div><div><h3>Methods</h3><div>English-speaking patients aged 18 or older with fallopian tubes who were scheduled for upcoming abdominal general, colorectal, or bariatric surgery were approached. A phone-administered questionnaire was used to collect demographics, clinical history, knowledge of OS, and likelihood to undergo OS if offered. Chi-square tests, Fisher’s exact tests, and odds ratios were calculated in R.</div></div><div><h3>Results</h3><div>153 patients were contacted, of which 68 were eligible and agreed to participate (44.4 % response rate). Of the 68 participants, 60 (88.2 %) were considered OS candidates (not interested in future fertility). The average age was 58, and 97 % of respondents self-identified as White. Forty-five respondents (75.0 %) were post-menopausal, 11 (18.3 %) had undergone a hysterectomy, and 16 (26.7 %) had undergone permanent contraception. Only 12 (20.0 %) knew OS reduces ovarian cancer risk. Among OS candidates, 15 (25.0 %) were likely to undergo OS during their upcoming surgery if offered. Predictors of likelihood to undergo OS during surgery include awareness of OS (50.0 % vs 19.0 %, OR 4.33, 95 % CI: 1.13–16.61, p = 0.025), family history of ovarian cancer (66.7 % vs 20.4 %, OR 7.82, 95 % CI: 1.26–48.35, p = 0.030), and interest in permanent contraception (100 % vs 25 %, p = 0.044).</div></div><div><h3>Conclusion</h3><div>Among patients with fallopian tubes undergoing non-gynecologic abdominal surgery, most were appropriate candidates for OS. Prior awareness of OS, family history of ovarian cancer, and interest in permanent contraception were associated with a greater interest in OS.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 102000"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145690325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robot-assisted transvaginal staging surgery using da Vinci SP for suspected ovarian borderline tumor: a case report","authors":"Naofumi Higuchi,&nbsp;Kiyoshi Kanno,&nbsp;Tomoka Kashiwabara,&nbsp;Taisuke Iwata,&nbsp;Yudai Sawai,&nbsp;Hiroshi Onji,&nbsp;Ryo Taniguchi,&nbsp;Masaaki Andou","doi":"10.1016/j.gore.2025.101987","DOIUrl":"10.1016/j.gore.2025.101987","url":null,"abstract":"<div><h3>Background</h3><div>Minimally invasive surgery is increasingly being applied in selected cases of ovarian borderline tumors and ovarian cancer. With the introduction of the da Vinci SP (SP) system, our institution began robot-assisted vNOTES (RAvNOTES) in 2023. This approach may overcome the limitations of conventional vNOTES, particularly limited triangulation (<span><span>Lowenstein et al., 2020</span></span>, <span><span>Hurni et al., 2022</span></span>, <span><span>Hurni and Huber, 2023</span></span>). We describe staging surgery for a suspected ovarian borderline tumor, performed using RAvNOTES.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101987"},"PeriodicalIF":1.3,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145576521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MECOM amplified endometrial cancer, a novel subset of copy number high tumors associated with poor prognosis","authors":"Shariska P. Harrington ,&nbsp;Jacqueline Romani ,&nbsp;Aminah Jatoi ,&nbsp;S.John Weroha ,&nbsp;Andrea Mariani ,&nbsp;William A. Cliby ,&nbsp;Jamie N. Bakkum-Gamez ,&nbsp;Dineo Khabele ,&nbsp;Alexandre Gaspar-Maia","doi":"10.1016/j.gore.2025.101993","DOIUrl":"10.1016/j.gore.2025.101993","url":null,"abstract":"<div><h3>Objective</h3><div>Copy number high (CNH) endometrial cancer (EC) is an aggressive molecular subgroup characterized by TP53 mutations and relative chemoresistance. CNH EC with cyclin E1 gene (<em>CCNE1</em>) amplification and erythroblastic oncogene B <em>(ERBB2)</em> amplification are associated with poor clinical outcomes. <em>MECOM</em>, a complex locus of MDS1 (myelodysplasia syndrome 1) and EVI1 (ecotropic virus integration site 1), has recently been associated with poor prognosis in ovarian cancer. Our objective was to evaluate clinical outcomes of <em>MECOM</em>, <em>CCNE1</em> and <em>ERBB2</em> amplified ECs and to provide a literature review on the role of <em>MECOM</em> in gynecologic cancers.</div></div><div><h3>Methods</h3><div>Copy number variation and molecular subtype classification were extracted from The Cancer Genome Atlas for 529 ECs. Amplification status was determined for <em>MECOM</em>, <em>CCNE1</em> and <em>ERBB2.</em> Measured clinical outcomes were overall and progression-free survival, covariates included race, stage at diagnosis, and tumor histology. A comprehensive search of peer-reviewed articles was undertaken to summarize evidence on the role of <em>MECOM</em> in gynecologic cancers.</div></div><div><h3>Results</h3><div>Of all ECs profiled, <em>MECOM</em> was the most frequently amplified gene. Notably, 35% of CNH ECs were <em>MECOM</em> amplified. In multivariate analysis, <em>MECOM</em> amplification without co-amplification of <em>CCNE1</em> or <em>ERBB2</em> was associated with an increased risk of death and recurrence, HR 2.3 [1.17–4.62], p = 0.0163 and HR 2.07 [1.08–3.98], p = 0.0282, respectively. The literature review identified 19 relevant studies with inconsistent evidence on <em>MECOM’s</em> role in carcinogenesis.</div></div><div><h3>Conclusions</h3><div>ECs with <em>MECOM</em> amplification are associated with poor clinical outcomes, even in the absence of <em>CCNE1</em> or <em>ERBB2</em> amplification. The current literature is limited, and further studies are warranted to determine the role of <em>MECOM</em> amplification in ECs.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101993"},"PeriodicalIF":1.3,"publicationDate":"2025-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145576520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contribution of laparoscopic surgery to the diagnosis of ovarian metastasis from thymoma: A rare case and review of the literature","authors":"Yui Sejimo ,&nbsp;Kenichi Makino ,&nbsp;Masato Waga ,&nbsp;Enami Kaneko ,&nbsp;Takeo Hirakawa ,&nbsp;Tae Sugawara ,&nbsp;Taichi Yoshida ,&nbsp;Hiroyuki Shibata ,&nbsp;Hiroshi Nanjo ,&nbsp;Yukihiro Terada","doi":"10.1016/j.gore.2025.101992","DOIUrl":"10.1016/j.gore.2025.101992","url":null,"abstract":"<div><h3>Background</h3><div>Thymoma is a rare mediastinal tumor that usually remains confined to the thoracic cavity. Extrathoracic metastasis is uncommon, and ovarian involvement is extremely rare. Only a few cases have been reported. Laparoscopic surgery provides a minimally invasive option for diagnosis and treatment in such unusual presentations.</div></div><div><h3>Case presentation</h3><div>A 53-year-old woman with a history of thymoma treated with surgery, chemotherapy, and radiotherapy was found to have a mildly enlarged right ovary and a nodule in the pouch of Douglas five years after initial therapy. Because peritoneal dissemination of thymoma is rare, a primary ovarian tumor was suspected. Diagnostic laparoscopy was performed, resulting in bilateral salpingo-oophorectomy and resection of peritoneal nodules. Histopathology confirmed bilateral ovarian metastases and peritoneal dissemination from thymoma. The patient recovered uneventfully and resumed systemic chemotherapy.</div></div><div><h3>Conclusion</h3><div>Ovarian metastasis from thymoma is extremely rare but should be considered in patients with a history of thymoma presenting with adnexal masses. This case underscores the diagnostic and therapeutic utility of laparoscopic surgery. Our findings add to the limited literature on extrathoracic spread of thymoma and highlight the role of minimally invasive techniques in such diagnostic challenges.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101992"},"PeriodicalIF":1.3,"publicationDate":"2025-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145576515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alectinib as salvage therapy for metastatic UIMT following misdiagnosis: A case enabling definitive surgery and prolonged remission","authors":"Ting Shuang ,&nbsp;Xiao lin Wang ,&nbsp;Yuanyuan Wang ,&nbsp;Bao li Jun","doi":"10.1016/j.gore.2025.101994","DOIUrl":"10.1016/j.gore.2025.101994","url":null,"abstract":"<div><h3>Background</h3><div>Uterine inflammatory myofibroblastic tumor (UIMT) is a rare, aggressive tumor often mistaken for uterine fibroids. This case report discusses managing advanced UIMT after a misdiagnosis and assesses the effectiveness of the anaplastic lymphoma kinase (ALK) inhibitor, alectinib, as a targeted treatment.</div><div>Case presentation</div><div>A 29-year-old woman had a laparoscopic myomectomy for presumed uterine fibroids. Three months later, she developed abdominal distension, vaginal bleeding, and fever. Pathological evaluation confirmed a diagnosis of UIMT with aggressive behavior, and imaging showed extensive abdominal metastases. She received supportive therapies including hepatoprotection, infection control, and hemostasis. Due to the substantial tumor burden and malnutrition, targeted therapy with the ALK inhibitor alectinib was initiated, informed by ALK-p80 positivity on IHC. Her symptoms relieved significantly, and pelvic masses reduced by 53.9 % after two treatment cycles. She subsequently underwent a total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and resection of pelvic and abdominal lesions. Post-surgery, she continued alectinib with no recurrence for over 10 months till now. Next-generation sequencing (NGS) revealed an FN1-ALK fusion and a novel MTAP-CDKN2A fusion.</div></div><div><h3>Conclusions</h3><div>This case highlights the significant efficacy and safety of alectinib in the management of advanced, recurrent, and aggressive UIMT, while also emphasizing the essential role of multidisciplinary management. It provides valuable insights and serves as a reference for the management of similar rare cases.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101994"},"PeriodicalIF":1.3,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145576517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case report of total epidermal necrosis following mirvetuximab soravtansine extravasation","authors":"Oriana Krivenko,&nbsp;Jenna Scott Powers,&nbsp;Connor C. Wang,&nbsp;Olivia W. Foley,&nbsp;Emily Hinchcliff,&nbsp;Emma Barber,&nbsp;Dario Roque","doi":"10.1016/j.gore.2025.101991","DOIUrl":"10.1016/j.gore.2025.101991","url":null,"abstract":"<div><h3>Background</h3><div>Mirvetuximab soravtansine (MIRV) is an antibody–drug conjugate (ADC) approved for the treatment of platinum-resistant ovarian cancer. We report the first known case of total epidermal necrosis secondary to MIRV extravasation, representing an unreported adverse event.</div></div><div><h3>Case</h3><div>A 74-year-old woman with recurrent high-grade serous carcinoma of the peritoneum who developed extensive soft tissue injury following peripheral intravenous extravasation of MIRV. Despite immediate cessation of the MIRV infusion and conservative management, the patient developed progressive cutaneous toxicity, including full-thickness epidermal necrosis, requiring an 18-day hospitalization and wound care at a regional burn center. No surgical intervention was required. Management included topical therapies, reduced dressing changes, systemic antibiotics, and vitamin D3. Following discharge, a central venous access device was placed, and she completed subsequent MIRV cycles without further complications.</div></div><div><h3>Conclusion</h3><div>This case underscores the potential for severe soft tissue injury from MIRV extravasation, despite its lack of vesicant labeling. Contributing factors may include the instability of its disulfide linker and the cytotoxicity of the DM4 payload. As MIRV and other ADCs become more widely used in clinical settings, establishing clear protocols for recognizing and managing extravasation is essential. Central venous access and standardized documentation may mitigate risk. Increased awareness and reporting are needed to inform clinical guidelines and ensure safe administration of ADC therapies.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101991"},"PeriodicalIF":1.3,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145576516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From intractable hiccups to optic neuritis: paraneoplastic neuromyelitis optica with leptomeningeal carcinomatosis in the setting of immature ovarian teratoma","authors":"Shannon Zhou ,&nbsp;Julie Szczygielski ,&nbsp;Boris Winterhoff ,&nbsp;Jordan Mattson","doi":"10.1016/j.gore.2025.101990","DOIUrl":"10.1016/j.gore.2025.101990","url":null,"abstract":"<div><h3>Background</h3><div>Paraneoplastic syndromes are associated with 10% of ovarian cancers. Neuromyelitis optica spectrum disorders (NMOSD), which can present with vision changes, paraplegia, vomiting, and/or intractable hiccups, are rarely associated with ovarian cancers. We present the first recorded case of NMOSD in the setting of malignant immature ovarian teratoma, with concurrent leptomeningeal carcinomatosis contributing to clinical presentation.</div></div><div><h3>Case</h3><div>We describe a 27-year-old patient with Stage IVB Immature Ovarian Teratoma complicated by leptomeningeal carcinomatosis, who initially presented with intractable hiccups, nausea, and vomiting, and eventually developed attenuated vision. Neurological workup revealed AQP4-IgG antibodies, suggesting neuromyelitis optica (NMO) as a paraneoplastic syndrome (PNS). The patient’s cancer was treated with tumor resection, BEP (bleomycin, etoposide, cisplatin) therapy, maintenance bevacizumab, and brain radiation. While symptoms suspicious for NMO presented early on, it was not until after tumor resection and the development of double vision that NMO was diagnosed. NMO was promptly treated with plasma exchange and high dose steroids. While therapies did lead to disease stabilization, she was left with residual neurologic deficits requiring gait assistance.</div></div><div><h3>Conclusion</h3><div>Early symptoms such as intractable hiccups, nausea, or vomiting may precede optic neuritis or myelitis and serve as initial warning signs of NMOSD. Clinicians should maintain a high index of suspicion and low threshold for neurology consultation and AQP4-IgG antibody titers, especially when neurologic symptoms are not fully explained by metastatic disease.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101990"},"PeriodicalIF":1.3,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145526038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory study of a long-term hospital-based cervical cancer screening program in a high HIV prevalence area of rural Malawi","authors":"Nora Badiner ,&nbsp;Laurel Guthrie ,&nbsp;Emily Stevenson ,&nbsp;Andrew Folkerts ,&nbsp;Joseph Mkandawire ,&nbsp;Roslyn YX Ghui ,&nbsp;Cassandra Graybill ,&nbsp;Ryan Hayton ,&nbsp;Moses Kasumba ,&nbsp;Linda Hong ,&nbsp;Sharon Lum ,&nbsp;Mark Reeves ,&nbsp;Yevgeniya Ioffe","doi":"10.1016/j.gore.2025.101986","DOIUrl":"10.1016/j.gore.2025.101986","url":null,"abstract":"<div><h3>Introduction</h3><div>Malawi has the second-highest incidence and highest cervical cancer-attributed mortality worldwide. National HIV prevalence is 7.7%. Malawi implemented the Cervical Cancer Control Plan in 1999. We conducted an exploratory study of a non-government, hospital-based cervical cancer screening program established in the Southern Region.</div></div><div><h3>Methods</h3><div>We performed a retrospective review of outcomes from a cervical cancer screening program at a 275-bed rural mission hospital from 1/2016 – 12/2021. Female patients 18 years and older presenting for cervical cancer screening were included. Outcomes included trends in screening modality, return screening rates, abnormal screening rates, and the COVID pandemic impact. Data abstracted included demographics, HIV status, screening modality, and follow-up information.</div></div><div><h3>Results</h3><div>15,432 patients were screened for cervical cancer during the study period, with an overall increase in annual number of patients screened, despite the COVID-19 pandemic. Screening was initially performed via Pap testing; Visual inspection with acetic acid became the most common screening modality in 2019 (69.4%).</div><div>HIV prevalence among screened patients increased over the study period to 82.0% in 2021 and was higher among return screening patients (89.0%). 4.3% of HIV-negative and 7.2% of HIV-positive women demonstrated abnormal screening results.</div></div><div><h3>Conclusion</h3><div>Despite the COVID-19 pandemic, the number of patients screened for cervical cancer annually increased over the study period. HIV prevalence in this study was much higher than the national prevalence. These results emphasize the successful collaboration between a national program, private hospital, and HIV treatment centers, and highlight the need to increase screening among healthy women in the community.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101986"},"PeriodicalIF":1.3,"publicationDate":"2025-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145526041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inverse correlation between Lamin A/C and survival in ovarian cancer: implications for predicting responsiveness to taxane-based chemotherapy","authors":"Elizabeth R. Smith ,&nbsp;Isaac R.L. Xu ,&nbsp;Kathy Qi Cai ,&nbsp;Sophia H.L. George ,&nbsp;Matthew P. Schlumbrecht ,&nbsp;Tian-Li Wang ,&nbsp;Ie-Ming Shih ,&nbsp;Xiang-Xi Xu","doi":"10.1016/j.gore.2025.101978","DOIUrl":"10.1016/j.gore.2025.101978","url":null,"abstract":"<div><h3>Objective</h3><div>Although paclitaxel is widely used to treat several solid cancers, the initial response rate in ovarian cancer is ∼60 %, but only ∼30 % in recurrent ovarian cancer. The basis of resistance remains poorly understood, and predictive biomarkers are currently unavailable. Nuclear Lamin A/C proteins determine the sturdiness of the nuclear envelope and were suggested to influence the sensitivity of the malignant cells to undergo paclitaxel-induced micronucleation and cell death. The relationship between Lamin A/C expression in ovarian cancer tissues and progression free survival (PFS) and overall survival (OS) in advanced ovarian cancer patients, most of whom had been treated at least once with platinum and taxane, was investigated.</div></div><div><h3>Methods</h3><div>Ovarian cancer samples in tumor microarrays were immunostained for Lamin A/C and analyzed for Lamin A/C expression in tumor cells. On the basis of this expression, tumors were stratified as either Lamin A/C-low or Lamin A/C-high. Overall survival and PFS were assessed using Kaplan-Meier plots.</div></div><div><h3>Results</h3><div>Both age and Lamin A/C expression correlate with OS, where older (&gt; 60 years) and higher Lamin A/C expression aligned with lower survival. Lamin A/C expression was a predictor of OS independently of age. The median OS for the Lamin A/C-low group was 58 months versus 34.5 months for the high-expression group.</div></div><div><h3>Conclusions</h3><div>A significant correlation was found between Lamin A/C expression and OS, which implies that strong, widespread Lamin A/C expression in primary tumor tissues may be a predictive marker for paclitaxel sensitivity and thus survival, supporting a proposed paclitaxel mechanism in inducing micronucleation of cancer cells.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101978"},"PeriodicalIF":1.3,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145526042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative outcomes of laparoscopic versus robotic-assisted laparoscopic techniques in the surgical staging of endometrial cancer: A systematic review and meta-analysis","authors":"Atieh Karimzadeh ,&nbsp;Ali Kazemi Abadi ,&nbsp;Hani Ghadri ,&nbsp;Sevil Hakimi ,&nbsp;Leila Allahqoli ,&nbsp;Veronika Günther ,&nbsp;Afrooz Mazidimoradi ,&nbsp;Hamid Salehiniya ,&nbsp;Antonio Simone Laganà ,&nbsp;Ibrahim Alkatout","doi":"10.1016/j.gore.2025.101980","DOIUrl":"10.1016/j.gore.2025.101980","url":null,"abstract":"<div><h3>Background</h3><div>Endometrial cancer (EC) is a prevalent gynecologic malignancy associated with escalating mortality rates. Surgical interventions continue to be the primary treatment modality for EC, with a growing utilization of minimally invasive surgeries (MIS) such as robotic-assisted laparoscopic surgery (RALS) and conventional laparoscopic surgery (CLS). Given the technical advantages of RALS, this study aimed to compare the surgical outcomes of RALS and CLS in the management of EC.</div></div><div><h3>Methods</h3><div>A systematic search was conducted on three electronic databases, namely PubMed, Scopus, and ISI Web of Science, up to June 2024 with no date restriction. Randomized controlled trials and cohort studies that compared surgical outcomes, intraoperative parameters, and short-term postoperative outcomes between RALS and CLS in women with EC were included in the analysis. Data on age, body mass index (BMI)kg/m², dissected lymph nodes, operative time, estimated blood loss, intraoperative complications (conversion rate to laparotomy and injuries), and short-term postoperative outcomes (length of hospital stay and complications) in both groups were collected and analyzed using R software (version 4.2.3). Weighted mean and standardized mean differences (SMDs) with 95 % confidence intervals (CIs) were used for continuous outcomes, while binary outcomes were analyzed using pooled odds ratios (ORs) with 95 % CIs using random-effects models. The risk of bias in the included studies was assessed.</div></div><div><h3>Results</h3><div>Sixteen studies with 2,725 patients were included. RALS was associated with longer operative time (170.0 vs. 152.6 min; SMD = 0.5) but lower blood loss (109.1 vs. 180.1 mL; SMD = −0.66), fewer conversions to laparotomy (OR = 0.29), reduced intraoperative injuries (OR = 0.32), and shorter hospital stay (2.91 vs. 3.36 days; SMD = −0.4) compared to CLS. However, postoperative complications were more frequent with RALS (OR = 1.8). Most studies had methodological limitations, with over 70 % rated as “poor,” and substantial heterogeneity was observed.</div></div><div><h3>Conclusion</h3><div>RALS provides specific advantages over CLS, including reduced blood loss, fewer conversions, and shorter hospitalization, but it is associated with longer operative time and higher postoperative complication rates. Results may primarily reflect outcomes from high-volume or experienced surgeons, limiting generalizability. Further high-quality prospective studies, including detailed patient-level and surgeon experience data, are needed to clarify the relative benefits, cost-effectiveness, and long-term outcomes of RALS versus CLS.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101980"},"PeriodicalIF":1.3,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145526040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}